Acrivon Therapeutics(us:ACRV)
1.68
-17.24%
Updated on 2025-04-02
Open:1.99
Close:1.68
High:1.99
Low:1.56
Prev Close:2.03
Volume:569931.00
Turnover:1.01M
Turnover Ratio:1.82%
Shares:31.35M
MarketCap:52.67M
About Acrivon Therapeutics
Acrivon Therapeutics, Inc. develops drugs for clinical treatment. Its unique precision medicine platform is Acrivon Predictive Precision Proteomics (AP3). AP3 is used to generate proprietary OncoSignature companion diagnostics to identify patients who will benefit from the medicine. The company was founded by Peter Blume-Jensen and Kristina Masson in 2018 and is headquartered in Watertown, MA.
Company Name: Acrivon Therapeutics
Address: 480 Arsenal Way,Suite 100
Employees: 61
Fiscar Year: 12-31
IPO Date: 2022-11-15
Website: http://acrivon.com
CIK: 1781174
View all SEC Filings
About
Acrivon Therapeutics, Inc. develops drugs for clinical treatment. Its unique precision medicine platform is Acrivon Predictive Precision Proteomics (AP3). AP3 is used to generate proprietary OncoSignature companion diagnostics to identify patients who will benefit from the medicine. The company was founded by Peter Blume-Jensen and Kristina Masson in 2018 and is headquartered in Watertown, MA.
Address:480 Arsenal Way,Suite 100
Website:http://acrivon.com
Market Movers